Researchers of the Institute of Biotechnology and Biomedicine (IBB-UAB) have generated four peptides, molecules smaller than proteins, capable of self-assembling in a controlled manner to form nanomaterials. The research, published in the journal ACS Nano, was conducted by Salvador Ventura, Marta Díaz Caballero and Susanna Navarro (IBB-UAB), and included the collaboration of Isabel Fuentes and Francesc Teixidor (Institute of Materials Science of Barcelona, ICMAB-CSIC).
In biotechnology, generating functional synthetic amyloid structures to form nanostructures by imitating the natural generation process is not new. The assembly of proteins into stable fibres allows creating supramolecular shapes that no isolated protein can create, and which are used as nanoconductors, photovoltaic structures, biosensors and catalysts.
Quite recently, researchers began synthesizing prion protein sequences to form nanomaterials. The interest in these sequences lies in the fact that the proteins assemble in a slower and more controlled manner, forming highly ordered, nontoxic nanostructures. However, the fact that the sequence is so long, with over 150 amino acids, makes it very difficult and expensive to synthesise.
“We have demonstrated that an adequate design can permit the size of synthetic prion sequences to be reduced down to only 7 amino acids, while conserving the same properties. The four peptides we have fabricated are the shortest structures of this type created until now, and are capable of forming stable fibril assemblies,” says Salvador Ventura, researcher at the IBB and the UAB Department of Biochemistry and Molecular Biology.
Image Credit: Credit: IBB-UAB
News This Week
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble [...]
A technology developed at Vanderbilt University Medical Center has led to the discovery of an "ultra-potent" monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. The antibody [...]
Research has found a significant fall in levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, 6 months after the second dose of the Pfizer-BioNTech vaccine. Clinical evidence also suggests that the risk [...]
Are the COVID vaccines substantially different from/inferior to other vaccines in terms of their effectiveness? The issue raised, and I'm mostly paraphrasing here, is this: Most vaccines (e.g. measles, smallpox) have efficacy defined such [...]
The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them. The ability to grow and treat virtual tumors is an [...]
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]